We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) reported $2.39 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.2%. EPS of $2.95 for the same period compares to $4.05 a year ago.
The reported revenue represents a surprise of -2.88% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $3.16, the EPS surprise was -6.65%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Product- Multiple Sclerosis- Tysabri- Rest of world: $216.90 million compared to the $198.27 million average estimate based on 21 analysts. The reported number represents a change of +1.2% year over year.
Revenue- Product- Multiple Sclerosis- Tysabri- United States: $247.80 million compared to the $243.07 million average estimate based on 21 analysts. The reported number represents a change of -9.6% year over year.
Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world: $180.50 million versus the 21-analyst average estimate of $171.34 million. The reported number represents a year-over-year change of -13.9%.
Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States: $157.50 million versus $155.31 million estimated by 21 analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.
Revenue- Contract manufacturing, royalty and other revenue: $118.10 million versus the 25-analyst average estimate of $176.90 million. The reported number represents a year-over-year change of -38.4%.
Revenue- Anti-CD20 Therapeutic Programs: $435.80 million versus $439.72 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.
Revenue- Product- Multiple Sclerosis- Fampyra- Total: $23 million compared to the $22.23 million average estimate based on 24 analysts. The reported number represents a change of +0.4% year over year.
Revenue- Product- Multiple Sclerosis- Tysabri- Total: $464.70 million versus $443.70 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -4.9% change.
Revenue- Product, net: $1.83 billion versus $1.84 billion estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a -3.8% change.
Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total: $412.60 million versus $446.84 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change.
Revenue- Product- Multiple Sclerosis- Fumarate- Tecfidera- Total: $244.30 million versus $226.84 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -17.8% change.
Revenue- Product- Multiple Sclerosis- Fumarate- Vumerity- Total: $156.40 million compared to the $173.99 million average estimate based on 22 analysts. The reported number represents a change of +3.7% year over year.
Shares of Biogen Inc. have returned -1.4% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
Biogen Inc. (BIIB - Free Report) reported $2.39 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.2%. EPS of $2.95 for the same period compares to $4.05 a year ago.
The reported revenue represents a surprise of -2.88% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $3.16, the EPS surprise was -6.65%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product- Multiple Sclerosis- Tysabri- Rest of world: $216.90 million compared to the $198.27 million average estimate based on 21 analysts. The reported number represents a change of +1.2% year over year.
- Revenue- Product- Multiple Sclerosis- Tysabri- United States: $247.80 million compared to the $243.07 million average estimate based on 21 analysts. The reported number represents a change of -9.6% year over year.
- Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world: $180.50 million versus the 21-analyst average estimate of $171.34 million. The reported number represents a year-over-year change of -13.9%.
- Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States: $157.50 million versus $155.31 million estimated by 21 analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.
- Revenue- Contract manufacturing, royalty and other revenue: $118.10 million versus the 25-analyst average estimate of $176.90 million. The reported number represents a year-over-year change of -38.4%.
- Revenue- Anti-CD20 Therapeutic Programs: $435.80 million versus $439.72 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.
- Revenue- Product- Multiple Sclerosis- Fampyra- Total: $23 million compared to the $22.23 million average estimate based on 24 analysts. The reported number represents a change of +0.4% year over year.
- Revenue- Product- Multiple Sclerosis- Tysabri- Total: $464.70 million versus $443.70 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -4.9% change.
- Revenue- Product, net: $1.83 billion versus $1.84 billion estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a -3.8% change.
- Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total: $412.60 million versus $446.84 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change.
- Revenue- Product- Multiple Sclerosis- Fumarate- Tecfidera- Total: $244.30 million versus $226.84 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -17.8% change.
- Revenue- Product- Multiple Sclerosis- Fumarate- Vumerity- Total: $156.40 million compared to the $173.99 million average estimate based on 22 analysts. The reported number represents a change of +3.7% year over year.
View all Key Company Metrics for Biogen Inc. here>>>Shares of Biogen Inc. have returned -1.4% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.